|Venture Round, 10/2008 ||$50k|
|Series A, 3/2011 ||$2.4M|
|Series B, 8/2012 |
Millennium Life Sciences Fund
|Series B, 9/2013 ||$19.8M|
|Debt, 3/2012 ||$1.32M|
|Debt, 11/2013 ||$3.6M|
Sapheon is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease.
Sapheon Inc. is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease.
The company’s current focus is the VenaSeal Sapheon Closure System, a novel treatment for venous reflux disease. With full EU regulatory approval already in place, this game-changing approach to treating veins is poised to disrupt a $1 billion worldwide market.
The VenaSeal System uses a proprietary medical adhesive to close the saphenous vein, eliminating the need for surgery, ablation, anesthesia, or the use of harsh chemicals. Sapheon is actively preparing for U.S. clinical trials and FDA approval of the VenaSeal Sapheon Closure System.